How Long Does MOTS-c Stay in Your System? What the Pharmacokinetic Literature Reports

The short answer, stated plainly

Across the peer-reviewed papers summarised on this page, no human pharmacokinetic (PK) study of MOTS-c has been published that reports a half-life, a time-to-clearance, or a detection window. That is the honest starting point. The verified literature on MOTS-c is dominated by mechanism and disease-model work: researchers described MOTS-c as a mitochondrial-encoded, interferon-linked host defense peptide in an eLife report (PMID 42611943) and in the earlier preprint version of the same work (PMID 39553971). Those papers characterised biology, not blood-level decay curves.

Anything on this page that describes how peptides in general are eliminated is labelled as class-level pharmacology, not as a MOTS-c measurement. That distinction matters, because generic peptide half-life figures are frequently repeated online as though they were MOTS-c data. They are not.

What "stays in your system" actually means

The question folds together at least four different measurements, and they rarely give the same number:

• Plasma half-life — the time for a measured circulating concentration to fall by half after administration. This requires serial blood sampling and a validated assay.
• Time to functional clearance — usually estimated as roughly four to five half-lives, at which point most of an administered amount is no longer in circulation. It depends entirely on having a half-life to start from.
• Duration of biological effect — how long a downstream change (gene expression, inflammatory signalling, tissue protection) persists. This can far outlast the molecule itself.
• Detectability — whether a laboratory using a specific assay can distinguish administered peptide from background. For an endogenous peptide, this is a fundamentally harder problem than for a foreign drug.

What the verified MOTS-c literature measured

Read as a group, these papers answer "what does MOTS-c do?" far better than "how long does it last?" — the review of sepsis-induced cardiomyopathy explicitly framed the topic as mechanisms and translational potential rather than as completed human pharmacology (PMID 42633878).

Half-life: what is compound-specific and what is not

Compound-specific

Nothing in the verified set establishes a MOTS-c half-life in humans. Researchers administered exogenous MOTS-c to rat hearts and reported mitigation of myocardial ischemia-reperfusion injury in experimental and in silico models (PMID 41593376), which confirms that exogenous delivery has been studied in animals — but an efficacy experiment is not a PK experiment, and the study endpoints were tissue injury measures rather than plasma concentration-time curves.

General peptide pharmacology (class-level, not MOTS-c data)

For short, unmodified peptides as a class, elimination is typically dominated by enzymatic proteolysis in blood and tissue, by glomerular filtration and subsequent tubular catabolism in the kidney, and by cellular uptake. Peptides of low molecular weight without protective modification are generally cleared on a timescale of minutes rather than hours, which is why pharmaceutical development so often relies on structural changes — amino acid substitution, cyclisation, lipidation, albumin binding, or depot formulation — to extend exposure. These are textbook principles that apply broadly to peptides; they are not measurements taken from MOTS-c, and they should not be quoted as such.

Route of administration and what it does to exposure

Route is one of the few PK-relevant variables the verified MOTS-c literature touches directly. A 2023 study used an orally administered MOTS-c analogue and reported that it ameliorated dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis (PMID 36528071). Two points follow. First, the molecule in that work was an analogue, not the native sequence — analogues are engineered precisely because native peptides often survive the gastrointestinal tract poorly, and an analogue's kinetics cannot be assumed to match the parent peptide's. Second, a local gastrointestinal effect in a colitis model does not demonstrate systemic exposure; the study's endpoints were inflammatory and apoptotic markers, not plasma levels.

As a general pharmacology principle, oral, subcutaneous, intravenous and intraperitoneal routes produce markedly different peak concentrations and different apparent durations for the same peptide. Comparing a rodent intraperitoneal experiment to an oral analogue experiment, or either to a human, is not a like-for-like comparison.

Why endogenous production complicates "clearance"

MOTS-c is encoded within the mitochondrial genome and is present in people without any administration — the host defense work described it as an interferon-responsive peptide arising from the human mitochondrial genome itself (PMID 39553971). That has a direct consequence for the "how long until it's gone?" framing: there is no true zero. Any assay reading includes whatever the body is producing.

Human studies have measured that endogenous pool. A pilot study examined MOTS-c levels in relation to sarcopenia risk in chronic peritoneal dialysis patients (PMID 40005438), illustrating that circulating MOTS-c can be quantified in clinical populations and that levels are compared between groups rather than tracked as drug disappearance curves. Cross-sectional level measurement and pharmacokinetic sampling are different exercises, and the former does not yield a half-life.

Factors that plausibly change peptide clearance

The following are class-level determinants described in general peptide pharmacology. None has been quantified for MOTS-c in the verified literature; they are listed to explain why any future MOTS-c number would vary between individuals rather than to imply a known value.

• Kidney function. Small peptides are filtered and catabolised renally; impaired filtration alters exposure. Notably, the human data point available here came from a dialysis population (PMID 40005438), a group in which renal handling is by definition abnormal — a reminder that population characteristics shape measured levels.
• Protease activity in plasma and tissue, which differs with inflammation, illness and age.
• Molecular modification. Analogues are designed to resist degradation, as in the oral analogue used in the colitis work (PMID 36528071).
• Route and formulation, including whether a depot or carrier slows absorption.
• Assay choice. Immunoassays and mass-spectrometry methods have different sensitivities and may or may not distinguish fragments from intact peptide.
• Species. Rodent clearance is typically faster than human clearance for the same molecule; rat findings such as the ischemia-reperfusion work (PMID 41593376) do not translate directly into human timelines.

Drug testing: what is and is not screened for

Standard workplace, clinical and pre-employment urine or blood panels look for a defined list of substances — typically amphetamines, cannabinoids, cocaine metabolites, opiates, phencyclidine, and in expanded panels benzodiazepines, barbiturates, methadone or alcohol markers. MOTS-c is not on those panels and would not produce a positive result on them. Peptides of this kind are not detectable by the immunoassay chemistries those tests use.

Anti-doping laboratories are a separate universe: they run targeted mass-spectrometry methods, and a peptide is only detectable there if a validated method for that specific sequence has been developed and deployed. The verified literature summarised on this page contains no validated MOTS-c detection assay, no published detection window, and no anti-doping method paper. Athletes governed by sport organisations are subject to those organisations' current prohibited lists and rules, which change over time and are outside the scope of the research summarised here. Nothing on this page is legal, regulatory or medical advice.

A further technical obstacle, following from the endogenous nature of the peptide described in the host defense work (PMID 42611943), is that distinguishing an administered identical sequence from naturally produced peptide generally requires isotope-ratio or population-threshold approaches rather than simple presence/absence detection.

Exogenous MOTS-c and tolerability: What Studies Report

The verified set contains no human safety or adverse-event trial for administered MOTS-c. The available exogenous-administration data are preclinical: researchers reported that exogenous MOTS-c mitigated myocardial ischemia-reperfusion injury in rat heart models supported by in silico evidence (PMID 41593376), and a separate study reported that an orally administered MOTS-c analogue ameliorated experimental colitis by inhibiting inflammation and apoptosis (PMID 36528071). Neither report is a toxicology or tolerability study in people. A 2026 review of MOTS-c in sepsis-induced cardiomyopathy framed the field in terms of mechanisms and translational potential (PMID 42633878), which is the language used when human translation remains ahead rather than behind.

Because tolerability data are absent, no statement about "how long side effects last" can be supported from this literature, and none is offered here.

Limitations of the current picture

1. No human dose-ranging or PK trial appears in the verified set; the immunological characterisation papers addressed biology rather than kinetics (PMID 39553971).
2. Human measurements available here are observational levels in a specific clinical population rather than administered-peptide kinetics (PMID 40005438).
3. The one oral-delivery study used an analogue, so its handling may differ from the native sequence (PMID 36528071).
4. Animal-to-human extrapolation of clearance is unreliable for peptides, and the cardiac work was conducted in rat models (PMID 41593376).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, medication or investigational compound. It summarises what published studies measured and reported; it does not describe how anyone should use anything.

Related reading

• MOTS-c: what the research literature covers
• How long peptides stay in the system: general pharmacokinetics

References

• Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis (European Journal of Pharmacology, 2023)
• The Human Mitochondrial Genome Encodes for an Interferon-Responsive Host Defense Peptide (bioRxiv, 2024)
• MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study (Medicina, 2025)
• Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models (Naunyn-Schmiedeberg's Archives of Pharmacology, 2026)
• MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide (eLife, 2026)
• MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential (European Journal of Pharmacology, 2026)